NASDAQ: BNTCBenitec Biopharma Inc Stock
$6.86+0.14 (+2.08%)
Updated Apr 23, 2024
BNTC Price
$6.86
Fair Value Price
$0.75
Market Cap
$17.78M
52 Week Low
$1.86
52 Week High
$9.01
P/E
-63.52x
P/B
1.15x
P/S
136.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$61.00k
Earnings
-$21.81M
Gross Margin
100%
Operating Margin
-35,709.84%
Profit Margin
-35,754.1%
Debt to Equity
0.38
Operating Cash Flow
-$18M
Beta
0.52
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BNTC Overview
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BNTC scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BNTC ($6.86) is overvalued by 808.63% relative to our estimate of its Fair Value price of $0.75 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BNTC ($6.86) is not significantly undervalued (808.63%) relative to our estimate of its Fair Value price of $0.75 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BNTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more BNTC due diligence checks available for Premium users.
Be the first to know about important BNTC news, forecast changes, insider trades & much more!
BNTC News
Valuation
BNTC fair value
Fair Value of BNTC stock based on Discounted Cash Flow (DCF)
Price
$6.86
Fair Value
$0.75
Overvalued by
808.63%
BNTC ($6.86) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BNTC ($6.86) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BNTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BNTC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-63.52x
Industry
16.46x
Market
41.92x
BNTC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.15x
Industry
5.93x
BNTC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BNTC's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.8M
Profit Margin
0%
BNTC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BNTC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$21.4M
Liabilities
$5.9M
Debt to equity
0.38
BNTC's short-term assets ($20.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BNTC's short-term assets ($20.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BNTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.4M
Investing
$0.0
Financing
$39.0k
BNTC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BNTC vs Biotech Stocks
Benitec Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.